EA029833B9 - Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления - Google Patents

Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления

Info

Publication number
EA029833B9
EA029833B9 EA201300738A EA201300738A EA029833B9 EA 029833 B9 EA029833 B9 EA 029833B9 EA 201300738 A EA201300738 A EA 201300738A EA 201300738 A EA201300738 A EA 201300738A EA 029833 B9 EA029833 B9 EA 029833B9
Authority
EA
Eurasian Patent Office
Prior art keywords
reagent
vaccine
efficacy
subject
variants
Prior art date
Application number
EA201300738A
Other languages
English (en)
Other versions
EA029833B1 (ru
EA201300738A1 (ru
Inventor
Кристиане Дезель
Стефан Г.Е. Кауфманн
Зильке Бандерманн
Леандер Гроде
Original Assignee
Макс-Планк-Гезельшафт Цур Фёрдерунг Дер Виссеншафтен Е.В.
Вакцине Проект Менеджмент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Макс-Планк-Гезельшафт Цур Фёрдерунг Дер Виссеншафтен Е.В., Вакцине Проект Менеджмент Гмбх filed Critical Макс-Планк-Гезельшафт Цур Фёрдерунг Дер Виссеншафтен Е.В.
Publication of EA201300738A1 publication Critical patent/EA201300738A1/ru
Publication of EA029833B1 publication Critical patent/EA029833B1/ru
Publication of EA029833B9 publication Critical patent/EA029833B9/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к способам и наборам реагентов для определения эффективности вакцины, в частности туберкулезной вакцины. Способ включает детекцию Т-клеток, продуцирующих IL-17, у вакцинированного субъекта путем подвергания биологического образца, полученного от указанного субъекта и содержащего иммунные клетки указанного субъекта, рестимуляции иммуногеном с последующим определением наличия и/или количества IL-17. Иммуноген соответствует домену, способному вызывать иммунный ответ, выбранный из иммуногенных пептидов и полипептидов из M. bovis или M. tuberculosis или из их иммуногенных фрагментов. Причем вакцина представляет собой дефицитную по уреазе клетку Mycobacterium, которая содержит молекулу рекомбинантной нуклеиновой кислоты, кодирующую слитый полипептид, содержащий указанный домен и домен выхода из фаголизосом. Наборы реагентов содержат реагент для рестимуляции иммунных клеток и реагент для иммунологической детекции Т-клеток, продуцирующих IL-17.
EA201300738A 2010-12-21 2011-12-21 Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления EA029833B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
PCT/EP2011/073609 WO2012085099A1 (en) 2010-12-21 2011-12-21 Determination of the efficacy of an anti-mycobacterial vaccination

Publications (3)

Publication Number Publication Date
EA201300738A1 EA201300738A1 (ru) 2013-12-30
EA029833B1 EA029833B1 (ru) 2018-05-31
EA029833B9 true EA029833B9 (ru) 2018-06-29

Family

ID=45446021

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300738A EA029833B9 (ru) 2010-12-21 2011-12-21 Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления

Country Status (25)

Country Link
US (1) US8906389B2 (ru)
EP (1) EP2656070B9 (ru)
JP (1) JP6055780B2 (ru)
KR (1) KR101882040B1 (ru)
CN (1) CN103492877B (ru)
AU (1) AU2011347266B2 (ru)
BR (1) BR112013015878B1 (ru)
CA (1) CA2822715C (ru)
CU (1) CU20130084A7 (ru)
CY (1) CY1117412T1 (ru)
DK (1) DK2656070T3 (ru)
EA (1) EA029833B9 (ru)
ES (1) ES2569035T3 (ru)
HK (1) HK1192322A1 (ru)
HR (1) HRP20160558T1 (ru)
HU (1) HUE027781T2 (ru)
MX (1) MX345961B (ru)
PL (1) PL2656070T3 (ru)
PT (1) PT2656070E (ru)
RS (1) RS54770B1 (ru)
SG (1) SG191331A1 (ru)
SI (1) SI2656070T1 (ru)
SM (1) SMT201600149B (ru)
UA (2) UA112067C2 (ru)
WO (1) WO2012085099A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
EP1137769B1 (en) * 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
JP2001215224A (ja) * 1999-11-25 2001-08-10 Hitachi Chem Co Ltd 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット
JP4662925B2 (ja) 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
BRPI0606991A2 (pt) * 2005-02-14 2009-08-18 Wyeth Corp métodos para triar compostos de teste capazes de antagonizar a sinalização de il-17f, para diagnosticar um distúrbio relacionado com a sinalização aumentada de il-17f em um indivìduo, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-21, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-23, para purificar a proteìna il-17a natural, e para isolar heterodìmeros de il-17 a/il-17f substancialmente isentos de homodìmeros de il-17a e homodìmeros de il-17f, uso de uma quantidade terapeuticamente eficaz de um antagonista da sinalização de il-17f, composição farmacêutica, adjuvante de vacina, anticorpo isolado, proteìnas il-17f e il-17a isoladas, e, heterodìmero de il-17a/il-17f
BRPI0713133A2 (pt) * 2006-06-19 2012-03-27 Wyeth Corp métodos de modular il-22 e il-17
CN101329230B (zh) * 2008-07-14 2010-10-20 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
RU2473365C1 (ru) 2008-10-20 2013-01-27 Юниверсити Оф Цюрих Вакцина mycobacterium tuberculosis
AU2010273708B2 (en) * 2009-06-29 2015-10-01 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. DESEL, DORHOI A., BANDERMANN S., GRODE L., EISELE B., KAUFMANN S. H. E.: "Recombinant BCG �ureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses", THE JOURNAL OF INFECTIOUS DISEASES, vol. 204, no. 10, 15 November 2011 (2011-11-15), pages 1573 - 1584, XP055020207, ISSN: 00221899, DOI: 10.1093/infdis/jir592 *
JAY K. KOLLS: "Th17 cells in mucosal immunity and tissue inflammation", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER, BERLIN, DE, vol. 32, no. 1, 25 February 2010 (2010-02-25), Berlin, DE, pages 1 - 2, XP019800830, ISSN: 1863-2300 *
S. C. DE CASSAN, PATHAN A. A., SANDER C. R., MINASSIAN A., ROWLAND R., HILL A. V. S., MCSHANE H., FLETCHER H. A.: "Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 17, no. 7, 1 July 2010 (2010-07-01), pages 1066 - 1073, XP055020193, ISSN: 15566811, DOI: 10.1128/CVI.00047-10 *
YINYAO LIN, SLIGHT SAMANTHA R., KHADER SHABAANA A.: "Th17 cytokines and vaccine-induced immunity", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER-VERLAG, vol. 32, no. 1, 1 March 2010 (2010-03-01), pages 79 - 90, XP055020185, ISSN: 18632297, DOI: 10.1007/s00281-009-0191-2 *

Also Published As

Publication number Publication date
HRP20160558T1 (hr) 2016-06-17
CN103492877B (zh) 2015-04-01
DK2656070T3 (en) 2016-06-13
EP2656070B1 (en) 2016-03-09
CU20130084A7 (es) 2013-12-27
SI2656070T1 (sl) 2016-05-31
EP2656070B9 (en) 2017-01-04
KR20140020243A (ko) 2014-02-18
BR112013015878B1 (pt) 2020-10-27
US20130280739A1 (en) 2013-10-24
HK1192322A1 (en) 2014-08-15
KR101882040B1 (ko) 2018-07-25
BR112013015878A2 (pt) 2016-10-04
UA113282C2 (xx) 2017-01-10
AU2011347266A1 (en) 2013-07-25
RS54770B1 (sr) 2016-10-31
SMT201600149B (it) 2016-07-01
ES2569035T3 (es) 2016-05-06
UA112067C2 (uk) 2016-07-25
JP6055780B2 (ja) 2016-12-27
EP2656070A1 (en) 2013-10-30
US8906389B2 (en) 2014-12-09
EA029833B1 (ru) 2018-05-31
CA2822715C (en) 2019-04-30
SG191331A1 (en) 2013-07-31
JP2014502841A (ja) 2014-02-06
PT2656070E (pt) 2016-06-17
PL2656070T3 (pl) 2017-01-31
EA201300738A1 (ru) 2013-12-30
CN103492877A (zh) 2014-01-01
CA2822715A1 (en) 2012-06-28
MX345961B (es) 2017-02-28
HUE027781T2 (en) 2016-11-28
AU2011347266B2 (en) 2016-07-21
WO2012085099A1 (en) 2012-06-28
MX2013007244A (es) 2014-01-17
CY1117412T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
MY173004A (en) Mycobacterial antigen vaccine
Babaki et al. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design
Vordermeier et al. Mycobacterium bovis antigens for the differential diagnosis of vaccinated and infected cattle
Mikkelsen et al. Review of Mycobacterium avium subsp. paratuberculosis antigen candidates with diagnostic potential
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
Raja et al. Heterologous DNA prime-protein boost immunization with RecA and FliD offers cross-clade protection against leptospiral infection
WO2009129521A3 (en) Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
EA029833B9 (ru) Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления
ES2875021T3 (es) Reactivos de diagnóstico para mejorar el diagnóstico inmunológico de tuberculosis in vivo o in vitro mediado por células
US10294531B2 (en) Method, kits and materials for detection of Lyme disease Borrelia sp. infection
Rodríguez-Alvarez et al. The secretome of a recombinant BCG substrain reveals differences in hypothetical proteins
Barkha et al. Immunochemical characterization of antigens of Brucella canis and their use in seroprevalence study of canine brucellosis
WO2015200833A3 (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)
Tan et al. Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis
CN107530414B (zh) 区分活动性结核病和潜伏结核感染的结核分枝杆菌抗原及其应用
MX2019003288A (es) Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.
Kwok et al. Expression and purification of diagnostically sensitive mycobacterial (Mycobacterium bovis) antigens and profiling of their humoral immune response in a rabbit model
Kalra et al. Evaluation of Mycobacterium tuberculosis specific RD antigens for delayed type hypersensitivity responses in guinea pig
MX2021004355A (es) Moleculas quimericas.
Kimiavimoghadam et al. EVALUATION OF HUMORAL IMMUNE RESPONSE IN TUBERCULOSIS PATIENTS THAN RECOMBINANT TB10. 4 ANTIGEN BY ELISA METHOD
Sánchez-Barinas et al. Research Article Specific Binding Peptides from Rv3632: A Strategy for Blocking Mycobacterium tuberculosis Entry to Target Cells?
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
Ghaffar et al. Isolation and characterization of Mycobacterium tuberculosis strain: Construction of recombinant fusion protein for control of tuberculosis
Manimaran et al. Immune responses against different inactivated vaccines of Mycoplasma mycoides subsp. capri in goats
Mikkelsen et al. Paper III

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM